

WHAT IS CLAIMED IS:

1. A protein comprising an amino acid sequence of SEQ ID No. 1 of sequence listing, or an amino acid sequence at least partly homologous or analogous to said sequence, and having proliferation inhibitory activity on cancer cells or cell death inducing activity, and its fragments.
- 10 2. A protein comprising an amino acid sequence homologous to said amino acid sequence of SEQ ID No. 1 of sequence listing, and having proliferation inhibitory activity on cancer cells or cell death inducing activity.
- 15 3. A protein comprising amino acids 61-89 and 497-514 of SEQ ID No. 1 of said sequence listing, and having proliferation inhibitory activity on cancer cells or cell death inducing activity.
- 20 4. A gene coding said protein defined in any one of claims 1 to 3 or its fragment.
- 25 5. A gene comprising DNA sequence of SEQ ID No. 2 of sequence listing, or DNA sequence at least partly homologous or analogous to said sequence.

6. A monoclonal antibody to said protein as defined in any one of claims 1 to 3 or its fragment.

7. The monoclonal antibody of claim 6 selected from 5 the group consisting of I38A (NATIONAL INSTITUTE OF BIOSCIENCE AND HUMAN TECHNOLOGY, AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY, International Deposit No. FERM BP-5872), monoclonal antibody I32D (NATIONAL INSTITUTE OF BIOSCIENCE AND HUMAN TECHNOLOGY, AGENCY OF 10 INDUSTRIAL SCIENCE AND TECHNOLOGY, International Deposit No. FERM BP-5873), and monoclonal antibody I310H (NATIONAL INSTITUTE OF BIOSCIENCE AND HUMAN TECHNOLOGY, AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY, International Deposit No. FERM BP-5874).

15

8. A reagent for qualifying apoptosis comprising at least one member selected from the group consisting of said protein as defined in any one of claims 1 to 3 and its fragment, said monoclonal antibody defined in claim 20 6, said monoclonal antibody defined in claim 7, and mixtures thereof.

9. A carcinostatic agent comprising said protein as defined in any one of claims 1 to 3 and its fragment 25 as an active component.

10. The carcinostatic agent of claim 9 further

comprising said monoclonal antibody as defined in claim
6 or 7.